Study of gut microbes and blood chemicals in IgA kidney disease
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial looks at how bacteria in the gut (microbiome) and substances in the body (metabonomics) relate to IgA nephropathy, a kidney condition. The goal is to understand patterns that may help explain the disease and improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 16 or older
- Your IgA nephropathy was confirmed by a kidney biopsy
- You haven’t taken antibiotics or probiotic/prebiotic supplements for at least 1 month before the sample
- You haven’t used steroid hormones or immune-suppressing medicines in the last 6 months
- Your diet and medicines haven’t changed for at least 1 month before the sample
- You don’t have other immune/autoimmune diseases, like lupus (SLE)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at lab markers (“biomarkers”) in people with IgA nephropathy, using kidney biopsy tissue. It may help researchers find better ways to understand the disease and tailor future care.
This trial enrolls teens and adults with biopsy-proven IgA nephropathy to help doctors learn whether a specific care approach works better for high-quality treatment. It is meant for people whose IgA kidney disease is the primary form (not caused by another illness).
This trial tests a medicine called CM313 in people with IgA nephropathy, a kidney disease. It may help reduce protein in the urine, which is a sign of kidney damage.
This study tests whether a new drug called BHV-1400 can slow down or help IgA nephropathy, a condition where the immune system damages the kidneys. You'll be monitored to see if the drug is safe and effective for you.
This study gathers information from people with IgA nephropathy to better understand how the disease changes over time and what can be expected. The goal is to improve care and help guide future treatments.
This trial is testing if adding another approved drug to standard treatment can slow kidney function decline in people with IgA nephropathy. It aims to find better options for South Asian adults with this condition.
Hear when a new IgA Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.